Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM London, UK and Chicago, IL – 15 December 2025 – Leucid Bio (“Leucid” or the
Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
London, UK – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral
NodThera Announces Appointment of Chris Guiffre, J.D., M.B.A., as Chief Financial Officer
Boston, MA – NodThera, a clinical-stage biotech pioneering a paradigm shift in the treatment of chronic inflammatory diseases through NLRP3 inhibition, today announced the appointment of
NodThera Announces First Patients Dosed in RESOLVE-2 Clinical Trial Evaluating Oral NT-0796 in Combination with a GLP-1 Receptor Agonist
Boston, MA, – NodThera, a clinical-stage biotech pioneering a paradigm shift in the treatment of chronic inflammatory diseases through NLRP3 inhibition, today announced that the first
Nyra Medical Announces Initiation of First-in-Human Clinical Trial for Novel Mitral Valve Repair Device
ATLANTA /PRNewswire/ — Nyra Medical, a leading innovator in structural heart therapies, announced today the initiation of its first-in-human clinical study evaluating its novel Cardiac
Macomics Announces Neurodegeneration and Neuroinflammation Applications of ENIGMAC Drug Discovery Platform
Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in neurodegeneration and neuroinflammation applications. Macomics’ ENIGMAC drug discovery
Harness Therapeutics Announces Launch of MISBA® Duo Platform and Research Collaboration with Ono Venture Investment
Cambridge, UK, : Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable targets to transform the treatment of neurodegenerative diseases, today announces the establishment of the
NodThera Demonstrates Reversal of Neuroinflammation and Inflammation in Parkinson’s Disease with Oral NLRP3 Inhibitor
Philadelphia, PA, – NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the